Comparing low-dose exemestane and tamoxifen for high-risk postmenopausal women
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two low-dose hormone blockers (exemestane and tamoxifen) to see which one is better at preventing breast cancer in postmenopausal women who are at high risk. You will have a 50% chance of getting either drug, and the study will follow you for several years to compare their effectiveness and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are postmenopausal (no periods for at least 12 months).
- You have a high risk of breast cancer, such as: recent non-invasive breast cancer (DCIS) treated with lumpectomy and possibly radiation, or certain non-cancerous breast changes (atypical hyperplasia, lobular carcinoma in situ), or a high calculated risk (≥3% in 5 years), or a CHEK2/ATM gene mutation, or you had chest radiation before age 30.
- You are generally healthy (able to do everyday activities, ECOG 0-1).
- No prior blood clots, endometrial cancer, severe osteoporosis, or certain eye conditions.
- You have not taken hormone replacement therapy in the last 3 months or antiestrogens in the last 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two low-dose medications, exemestane and tamoxifen, to see which is better at preventing breast cancer in postmenopausal women who have a higher risk. You would take one of these pills daily for a few years, and the study will check how well it works and what side effects occur.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
This study looks at whether taking hormone-blocking pills for longer than 5 years can help lower the risk of breast cancer returning. It is for people who had lymph node involvement and have already completed their initial 5-year treatment without the cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.